Search

BackgroundCOVID-19 is still a challenge, both with regard to its treatment and to the actual efficacy of the vaccines available to date, especially with the emergence of new variants. We evaluated the efficacy of the measles-mumps-rubella (MMR) vaccine in preventing SARS-CoV-2 infection and severity of COVID-19 in health workers.MethodsThis analysis includes data from one ongoing blinded, randomized, placebo-controlled trial with participants aged 18-60 years were randomly assigned to receive the MMR vaccine or a placebo. The primary efficacy analysis included all participants with a positive nasopharyngeal RT-PCR test since their inclusion.ResultsThe MMR vaccine did not prevent the SARS-CoV-2 infection. Participants in the MMR group, compared with those in the placebo group, had a 48% risk reduction in symptomatic COVID-19 (RR = 0.52; 95% CI: 0.33–0.83; p=0.004) and a 76% risk reduction in COVID-19 treatment (RR = 0.24; 95% CI: 0.06 – 0.88; p = 0.020) with one dose and a 51% risk reduction in COVID-19 symptoms (RR = 0.49; 95% CI: 0.31 – 0.78; p = 0.001) and a 78% risk reduction in COVID-19 treatment (RR = 0.22; 95% CI: 0.06 – 0.82; p = 0.015) with two doses.ConclusionsThis interim analysis of an ongoing clinical trial suggests that compared with a placebo, the vaccine reduces the risk of COVID-19 symptoms and reduces the need for COVID-19 treatment.Clinical Trials RegistryBrazilian Clinical Trials Registry (ReBEC n° RBR-2xd6dkj - https://ensaiosclinicos.gov.br/rg/RBR-2xd6dkj).HIGHLIGHTSThe MMR vaccine can stimulate the innate immunity inducing a nonspecific protection against other infections, called heterologous immunity.Repeated exposure to the antigen (innate immune response training) results in an extension of the action time of this immune response (innate immune response memory) and consequently in protection against other infections (heterologous immunity) for a longer time.The MMR vaccine has been used by national immunization programs in the world for many years, it is very safe and can be stored and distributed at 2-8°C, making it particularly suitable for global distribution.Among participants who received at least one dose, compared with those in the placebo group, participants in the MMR group had a significant risk reduction in symptomatic COVID-19 and of cases requiring treatment.The use of MMR vaccine can be useful in several populations in the world that do not have access to the COVID-19 vaccine and in a future epidemic or pandemic as an emergency measure until specific treatments or vaccines for each case are available to the general population.

Objective: to analyze the sociodemographic and clinical profile of women with gynecological cancer in brachytherapy. Method: a cross-sectional study including records of 1,930 visits of women in brachytherapy assisted between 2006-2016 in Santa Catarina (Brazil). Collection was performed in 2019, in an institutional bank, submitted to frequency measurements, chi-square test, 95% confidence intervals, significance level of 0.05. Results: women aged 40-59 years (47.2%), white (93.3%); with elementary school (65%); cervical cancer (78.5%); stages II-III (73.3%) figured prominently. In the comparison of staging proportions in the topography variable, a higher proportion of malignant neoplasm of cervix uteri unspecified in the grouped III-IV staging (84.6%). Conclusion: the profile analysis shows the need for screening and health education for prevention and/or early detection of gynecological cancers and training of nurses specialized in radiotherapy to care for women’s health. RESUMEN Objetivo: analizar el perfil sociodemográfico y clínico de mujeres con cáncer ginecológico en braquiterapia. Método: estudio transversal que incluyó registros de 1.930 visitas de mujeres en braquiterapia asistidas entre 2006-2016 en Santa Catarina (Brasil). La recolección se realizóen 2019, en un banco institucional, sometida a medidas de frecuencia, pruebachi-cuadrado, intervalos de confianza al 95%, nivel de significancia de 0,05. Resultados: predominaron las mujeres entre 40-59 años (47,2%), blancas (93,3%); con educación primaria (65%); cáncer de cuello uterino (78,5%); en estadios II-III (73,3%). Al comparar las proporciones de estadificación en la variable topografía, encontramos una mayor proporción de malignidad cervical no especificada la estadificación agrupada III-IV (84,6%). Conclusión: el análisis del perfil muestra la necesidad de cribado y educación sanitaria para la prevención y/o detección temprana de cánceres ginecológicos y la formación de enfermeras especializadas en radioterapia para el cuidado de la salud de la mujer. RESUMO Objetivo: analisar o perfil sociodemográfico e clínico de mulheres com câncer ginecológico em braquiterapia. Método: estudo transversal incluindo registros de 1.930 atendimentos de mulheres em braquiterapia assistidas entre 2006-2016 em Santa Catarina (Brasil). Coleta foi realizada em 2019, em banco institucional, submetida às medidas de frequência, Teste Qui-Quadrado, intervalos de 95% de confiança, nível de significância de 0,05. Resultados: predominaram as mulheres entre 40-59 anos (47,2%),brancas (93,3%); com ensino fundamental (65%); câncer do colo do útero (78,5%); nos estádios II-III (73,3%). Na comparação das proporções dos estadiamentos na variável topografia, encontrou-se uma maior proporção da neoplasia maligna do colo do útero não especificada nos estadiamentos III-IV agrupados (84,6%). Conclusão: a análise do perfil mostra a necessidade do rastreamento e educação em saúde para prevenção e/ou detecção precoce dos cânceres ginecológicos e a formação de enfermeiros especialistas em radioterapia para atendimento da saúde da mulher.